Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.
about
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.Immunohistochemical expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in invasive breast carcinomaLow expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium.Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node.Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.
P2860
Q27852459-18D11899-7C3B-4C22-A352-34C1B961BA84Q33880656-BADDCFAA-8F63-4757-8D43-0CA88E12F10FQ33902738-5A206255-E379-4AEB-AE29-A54873B7A460Q36903127-01EC00B2-D4BE-4E42-B4CB-C06BD99FEDE0Q38406512-DCBA4308-02B7-4AD6-96A1-416D437A072FQ38822034-0CD4002A-4554-44B9-80DD-8E0DD092B5C5Q38923020-E845579E-F0A2-4274-895B-06D6A3A47E81Q39119200-9046FB27-ABAF-4E42-AF85-D19C0E41D47DQ39207632-ED1EA824-E50A-4E2A-8BDA-4ABE63B1D49CQ39656658-F32F206A-C5B1-4DC7-9F13-084E2E4BF2CFQ42127261-A6B5C70C-F25F-45C8-A44A-0FFA08AE2F96Q42375660-79266DF9-1D84-4A23-A455-3E43E647FC78Q47832318-51DBD144-0F69-4D18-BE30-0FF3660F0584Q48230920-BDCF1387-3558-41F7-82E8-889C5A6CE071Q51155840-DCF0905E-0430-4FA5-AE41-756FF81045EBQ54549875-B1E6650B-1B6C-47CC-82CE-93D1A50528F4Q55059317-742214A5-A1F3-47B1-B9CF-9CD6C2D0901A
P2860
Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Characterization of anti-TIMP- ...... xed, paraffin-embedded tissue.
@en
type
label
Characterization of anti-TIMP- ...... xed, paraffin-embedded tissue.
@en
prefLabel
Characterization of anti-TIMP- ...... xed, paraffin-embedded tissue.
@en
P2093
P2860
P356
P1476
Characterization of anti-TIMP- ...... xed, paraffin-embedded tissue.
@en
P2093
Claus Fenger
Henrik Winther
Irene Vejgaard Sorensen
Niels T Foged
Nils Brünner
Pernille A Usher
Ulrik Lademann
P2860
P304
P356
10.1369/JHC.5A6896.2006
P577
2006-03-03T00:00:00Z